The only international event dedicated to discussing regulatory, ethical and operational aspects of running clinical trials in Russia
1 - 2 December 2020
Marriott Grand Hotel, Moscow, Russia
Deputy Head of the Division for Coordination of Work on Pharmaceutical Drugs and Medical Devices Circulation, Department for Technical Regulation and Accreditation
Eurasian Economic Commission
Site Relationship Partner (Director), Russia and Belarus
Pfizer
Chief Scientific Officer
Novartis Pharma, Russia
Data Generation & Scientific Communication Lead, Medical Affairs
Sanofi
Deputy Head of the Division on Medical Devices Expertise and Safety Monitoring
National Institute of Quality of Roszdravnadzor
Head of Medical Projects Group
Takeda
Medical director
IPHARMA
KEY TOPICS & FEATURES IN 2020:
o The current status of the clinical trials market: what are the latest trends in Russia and globally?
o Clinical trials during the Covid-19 pandemic: practical experiences, challenges and solutions found
o Clinical trials in the Eurasian Union - registration practices and common rules in action
o Acceleration of digitalisation in clinical trials: AI, remote monitoring, electronic registers, access to data and data safety
o RWE - globally and in Russia: RWE as a key tool for the federal project “Digital technologies”
o Live Interviews with sponsors and research & investigators centres
Insights from 40+ experts: regulators, representatives of international and Russian pharmaceutical producers, CROs and investigators
2-day information-rich programme that includes insightful presentations from leading sector players, interactive debates and round tables
Unrivalled networking opportunities with 150+ attendees from such companies as AstraZeneca, Pfizer, Novartis, Bayer, Biocad, R-Pharm and many more
Unique opportunity for all the clinical trials sector players to meet and discuss the most burning issues.
The forum brings together representatives of all stakeholder groups involved in clinical trials – sponsors, CROs, regulators and investigators for a constructive dialogue aimed at improving all future processes.
Very good overview of a large number of clinical trial topics and the specifics of the Russian market.
Very interesting insight into the latest developments in the Russian market.
